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Conclusions: Preliminary data of this study suggest that CS
alone or in combination with GS is able to decrease signiﬁcantly
synovitis as measured by US. The decrease in synovitis after
SYSADOA treatment has been correlated with an improvement
in knee pain. The decrease in synovitis elicited by SYSADOA
treatment in this retrospective study is in accordance with former
reduction of synovitis signs shown by CS in other studies and
could contribute to explain its symptomatic and structure disease
modifying effects.
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Purpose: To determine the associations between serum levels of
inﬂammatory markers, radiographic osteoarthritis (OA) and knee
cartilage loss over time in older adults.
Methods: A total of 193 randomly selected subjects (mean 63
years, range 51-78, 47% female) were studied at baseline and 2.9
years later. Serum high-sensitivity C-reactive protein (hs-CRP),
interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) were as-
sessed by radioimmunoassay. T1-weighted fat-suppressed MRI of
the right knee was performed to determine knee cartilage volume.
Knee radiographic osteoarthritis (ROA) was also assessed.
Results: At baseline, quartiles of IL-6 and TNF-α were associated
with increased prevalence of medial tibiofemoral joint space nar-
rowing (grade ≥1) in multivariable analyses (IL-6: OR=1.41 and
1.49 per quartile; TNF-α: OR=1.62 and 1.49 per quartile for right
and left knees, respectively; all P<0.05). Longitudinally, baseline
IL-6 (not TNF-α) predicted loss in both medial and lateral tibial
cartilage volume (β: -0.87% and -1.02% per annum per quar-
tile, P<0.05 and P<0.01, respectively). An increase in IL-6 was
associated with increased loss of medial and lateral tibial carti-
lage volume (β: -0.89% and -0.78% per annum per quartile, both
P<0.05), and change in TNF-α was also negatively associated
with change in medial and lateral tibial cartilage volume (β: -0.75%
and -0.80% per annum per quartile, both P<0.05). The associa-
tions of IL-6 and TNF-α were dependent, in part, on each other
except those between baseline IL-6 and cartilage loss. Serum
hs-CRP was not associated with ROA and cartilage loss.
Conclusions: Serum levels of IL-6 and, to a lesser extent, TNF-α
are associated with knee cartilage loss in older people suggesting
low level inﬂammation plays a role in the pathogenesis of knee
OA.
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RACIAL DIFFERENCES IN OSTEOARTHRITIS PAIN AND
FUNCTION: POTENTIAL EXPLANATORY FACTORS
K.D. Allen1,2, E.Z. Oddone1,2, C.J. Coffman1,2, F.J. Keefe2,
J.H. Lindquist1, H.B. Bosworth1,2
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Purpose: African Americans with osteoarthritis (OA) report greater
pain and functional limitations than Caucasians, but the reasons
for these racial disparities are not well understood. This study
examined factors underlying racial differences in pain and function
among patients with hip and/or knee osteoarthritis (OA), including
psychological variables that have not previously been examined in
this context.
Methods: Participants were n=491 African Americans and Cau-
casians enrolled in a clinical trial of telephone-based OA self-
management. All measures were obtained at baseline. Pain and
function were assessed using the Arthritis Impact Measurement
Scales-2 (AIMS2) subscales. Potential explanatory variables in-
cluded demographic factors (age, gender, marital status, educa-
tion, income, working status, health literacy), health-related factors
(body mass index, self-reported health, joint(s) with OA, duration
of OA symptoms, pain medication use, current exercise), and
psychological factors (arthritis self-efﬁcacy, problem- and emotion-
focused pain coping, AIMS2 affect subscale). The AIMS2 pain
subscale was also included in models of AIMS2 function. Potential
explanatory variables that were associated with both race and
pain or function, and that reduced the association of race with
pain or function by ≥10%, were included in the ﬁnal multivariable
linear regression models where racial differences in AIMS2 pain
and function scores were examined.
Results: In unadjusted linear regression models, African Ameri-
can race was associated with higher (worse) AIMS2 pain scores
(unadjusted B = 0.65, p<0.01) and higher (worse) AIMS2 func-
tion scores (unadjusted B = 0.59, p<0.01). African American race
was no longer signiﬁcantly associated with AIMS2 pain scores in
the ﬁnal regression model (B = 0.03, p=0.874); variables signif-
icantly associated with worse AIMS2 pain scores in that model
were: worse AIMS2 affect scores, greater emotion-focused cop-
ing, lower arthritis self-efﬁcacy, and fair or poor self-reported
health. African American race was also no longer signiﬁcantly
associated with AIMS2 function scores in the ﬁnal regression
model (B = 0.07, p=0.509). Variables signiﬁcantly associated with
worse AIMS2 function scores were the same as those described
above for AIMS2 pain scores. In addition, worse AIMS2 pain
scores were signiﬁcantly associated with worse AIMS2 function
scores.
Conclusions: Factors explaining racial differences in pain and
function were largely psychological, including AIMS2 affect (which
comprises mood and level of tension), use of emotion-focused
coping, and arthritis self-efﬁcacy. Self-management and psycho-
logical/behavioral interventions can inﬂuence these factors, and
greater dissemination of these programs among African Amer-
icans may be a key step toward reducing racial disparities in
OA-related pain and function.
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METALLOPROTEASE-13 GENES BY THE MICRORNAS
MIR-140 AND MIR-27A IN HUMAN OSTEOARTHRITIC
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Purpose: MicroRNAs are small non-coding RNAs that regulate
target messenger RNA. We investigated the implication of two
miRNAs, miR-140 and miR-27a, in MMP-13 and IGFBP-5 gene
regulation in human osteoarthritic (OA) chondrocytes.
Methods: Gene expression was determined by real-time PCR.
The effect of each miRNA on IGFBP-5 and MMP-13 expres-
sion/production was evaluated by transiently transfecting their pre-
cursors (pre-miRNAs) and inhibitors (anti-miRNAs) into human
OA chondrocytes. Modulation of IGFBP-5, miR-140 and miR-27a
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expression was determined upon treatment of OA chondrocytes
with cytokines and growth factors.
Results: IGFBP-5 was expressed in human chondrocytes with
levels signiﬁcantly (p<0.04) lower in OA. Computational algo-
rithms identiﬁed miR-140 and miR-27a as possible regulators of
MMP-13 and IGFBP-5 expression. Data showed that both miR-
NAs were expressed in chondrocytes. There was a signiﬁcant
(p<0.01) reduction in miR-140 expression in OA, whereas miR-
27a expression was only slightly decreased. Transfection with pre-
miR-140 signiﬁcantly (p<0.005) decreased IGFBP-5 expression
at 24 hours, while pre-miR-27a did not affect either MMP-13 or
IGFBP-5. Treatment with anti-miR-27a, but not with anti-miR-140,
signiﬁcantly increased the expression of both MMP-13 (p<0.05)
and IGFBP-5 (p<0.01) after 72 hours incubation. These data
indicate that IGFBP-5 is a direct target of miR-140, whereas miR-
27a indirectly down-regulates both MMP-13 and IGFBP-5. TGF-β
down-regulates miR-140 and up-regulates IGFBP-5.
Conclusions: This study is the ﬁrst to show the involvement of
miRNAs in human OA chondrocytes. Their effect on two genes
involved in OA pathophysiology adds another level of complexity
to gene regulation, which could open up novel avenues in OA
therapeutic strategy
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EVIDENCE FOR A ROLE OF DICKOPPF-3 IN THE
PATHOGENESIS OF OSTEOARTHRITIS
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Purpose: To identify genes showing altered expression in os-
teoarthritic cartilage and synovium. Dkk3, a member of the Dick-
oppf family of Wnt signalling antagonsists was overexpressed and
this work highlights the potential function of Dkk3 in OA.
Methods: Real-time PCR was used to compare expression of 270
cytokines, chemokines and their receptors in cartilage and syn-
ovium from OA and non-OA patients. Expression of Dkk3 during
chondrogenic differentiation of ATDC5 cells was also assessed
using real-time PCR and compared to ATDC5 cells not stimu-
lated to undergo chondrogenesis. The effect of TGFb on Dkk3
expression in chondrocytes was measured following treatment of
SW1353 cells with TGFb. To assess the distribution of Dkk3 in OA
cartilage immunohistochemistry was carried out on anteromedial
gonarthrosis specimens. The level of Dkk3 in synovial ﬂuid tricom-
partmental and unicompartmental cartilage lesions was measured
using ELISA.
Results: Several components of the Wnt pathway showed altered
expression between normal and OA tissue. Strikingly, the greatest
and most signiﬁcant change was in Dkk3 expression, with a 10-fold
increase in OA cartilage (p=0.00011) and a 3.5-fold increase in OA
synovium (p=0.007) when compared to respective control tissues.
Dkk3 expression decreased during chondrogenic differentiation of
ATDC5 cells and to be decreased following TGFβ treatment of
SW1353 cells.
Immunohistochemical analysis of specimens from individuals with
anteromedial gonarthrosis (AMG, a subtype of knee OA), demon-
strated Dkk3 protein in chondrocytes of the superﬁcial zones of
the cartilage, but not the deeper zones. Additionally there is an
increase in Dkk3 expression in superﬁcial zone chondrocytes in
damaged when compared to undamaged cartilage from within the
same knee. Using ELISA we have shown increased Dkk3 pro-
tein in the synovial ﬂuid of individuals with tricompartmental OA
(n=4) versus those with unicompartmental cartilage lesions (n=10)
(182ng/ml v 116 ng/ml, p<0.01, a single non-OA control synovial
ﬂuid measured 43ng/ml.
Conclusions: Dkk3 is a molecule with poorly ascribed function,
especially within the musculoskeletal system. In contrast to other
members of the Dkk family, Dkk3 does not act consistently as a
Wnt antagonist. Literature on a number of tumour-derived cells
shows that Dkk3 can potentially regulate Wnt, TGFβ, BMP, FGF
and Activin signalling and cell proliferation and apoptosis. These
cellular processes are highly relevant to OA. In this preliminary
study we have shown that Dkk3 is overexpressed in OA cartilage
and synovium. Interestingly, the increased expression of Dkk3 is
also detected at the protein level in the synovial ﬂuid; with in-
creased Dkk3 present as disease severity increases. Furthermore
Dkk3 protein in cartilage is detected more highly in damaged artic-
ular cartilage when compared to macroscopically normal cartilage.
The decreased expression of Dkk3 during chondrogenesis is sug-
gestive of a role of Dkk3 not only in articular cartilage maintenance
but also in development. We have also seen decreased expres-
sion of Dkk3 in response to TGFβ treatment. Our current work
aims to identify the function of Dkk3 in articular chondrocytes,
the signaling pathways activated by Dkk3 and the mechanisms
causing increased Dkk3 expression in OA.
Dkk3 is an intriguing molecule in the Wnt signalling ﬁeld since the
evidence for its function as a Wnt antagonist is at best equivocal.
Evidence for a role for Dkk3 in OA is compelling. Dissecting its
function in cartilage and OA will both shed light on its overall
molecular mechanism of action, enhance our knowledge of the
pathogenesis of OA and also uncover potential new therapeutic
targets for chondroprotection.
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JOINT INJURY LEADS TO SIGNIFICANTLY INCREASED
AGGRECANASE ACTIVITY IN HUMANS AND PRECLINICAL
ANIMAL MODELS
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Purpose: Traumatic joint injury in humans, irrespective of im-
mediate surgical intervention, increases the risk for osteoarthritis
(OA) development in later years. OA involves articular cartilage
degradation, characterized by release of aggrecan and collagen
fragments, and subsequent loss of tissue integrity and mechanical
properties. The evolution of this disease state from joint injury is
not clearly understood. Aggrecanases play a major role in cartilage
degradation, and ARGS-aggrecan generated by direct cleavage
of aggrecan core protein by aggrecanases is the most abundant
aggrecan fragment in OA synovial ﬂuid (SF). The current study
measures the level of aggrecanase generated ARGS-aggrecan
fragments in the SF of humans with joint injuries in comparison
to OA patients, and in preclinical animal models of joint injury, in
order to understand the evolution of disease from injury and to
facilitate pharmacologic intervention.
Methods: The ARGS-aggrecan ELISA used anti-aggrecan ab,
AHP0022 (Invitrogen) for capture, and BC-3 (Abcam) for detec-
tion. Aggrecan puriﬁed from human cartilage and cleaved with
ADAMTS4 served as standard, the range of detection was 10-500
ng aggrecan. SF from patients with anterior cruciate ligament rup-
ture (ACL, 53), meniscus injury (69), OA (11), and knee-healthy
reference subjects (8) from Lund University, Sweden were tested
for ARGS-aggrecan at appropriate dilutions. Joint instability was
induced in rats by medial meniscal surgery. SF lavage samples
were collected at 4 days, and at 1, 2, 3, 5 and 8 weeks post
surgery. ARGS-aggrecan levels were determined with contralat-
eral knees as controls.
Results: ARGS-aggrecan concentrations ranged from 2-590
μg/ml in human SF samples. ACL, meniscus injury and OA SF
